Médecins pour Thymome à l'étranger — Page 2

Le professeur Ondzhel est spécialisé en oncochirurgie, plus particulièrement dans les cancers colorectaux et rectaux, et réalise des interventions complexes à l'hôpital universitaire Medipol Mega.

• Formé à la Cleveland Clinic – leader en chirurgie colorectale
• Proctologue certifié par la Commission européenne avec plus de 25 ans d'expérience
• Recherches publiées sur l'adénocarcinome rectal et la résection de cancers multiviscéraux
• Chef du département de chirurgie de l'Université Medipol d'Istanbul
• Membre fondateur de l'Eurasian Colorectal Technologies Association

Le Dr Yildiz est spécialisé dans le thymome et les tumeurs neuroendocrines, avec de nombreuses recherches publiées dans des revues médicales internationales.

• Publier plus de 17 études sur des pathologies oncologiques rares
• Expertise dans le diagnostic et le traitement de cas complexes de thymome
• Travailler à l'hôpital universitaire Medipol Mega – un centre d'oncologie de premier plan

Le Pr. Univ. Dr. Wolfgang Köstler est un expert de premier plan dans les thérapies ciblées contre le cancer, avec plus de deux décennies d'expérience en oncologie médicale.

• Se spécialiser dans le cancer du sein et les tumeurs gynécologiques malignes
• Chef adjoint de la division clinique d'oncologie de l'Université médicale de Vienne
• Mettre l'accent sur la thérapie systémique individualisée du cancer et l'immunothérapie
• Recherche publiée sur le développement de biomarqueurs et la biologie tumorale

Le Professeur Walter Klepetko a été le pionnier des premières transplantations pulmonaires en Autriche et a mis en place l'un des plus importants programmes de chirurgie thoracique d'Europe à l'Université de médecine de Vienne.

• Plus de 40 ans de spécialisation en oncologie thoracique complexe et en transplantation pulmonaire
• Ancien chef de la chirurgie thoracique à l'Université de médecine de Vienne
• Développement de techniques mini-invasives avancées pour les tumeurs thoraciques
• Renommé pour la prise en charge de cas à haut risque et de résections complexes

Plus de 30 ans d'expérience en immunologie – Le Dr Jaunalksne se spécialise dans la virothérapie, un domaine de pointe pour le traitement du thymome.

• Diriger le centre d'immunologie clinique de l'hôpital universitaire clinique Pauls Stradins
• Diplômer de l'Institut médical de Riga avec un internat en médecine interne
• Se concentrer sur des approches immunologiques innovantes

Le Dr Alemdar est spécialisé dans le traitement du thymome et possède une vaste expérience en oncologie médicale dans les meilleurs hôpitaux turcs.

• Formé à l'Université d'Akdeniz – une institution médicale de premier plan en Turquie
• Plus de 15 ans d'expérience en oncologie et en médecine interne
• Travaille au Medical Park Antalya Hospital Complex – équipé d'installations de pointe pour le traitement du cancer
• Membre de l'Association turque d'oncologie médicale

Le Pr. agrégé Nail Paksoy apporte son expertise de l'Institut d'oncologie de l'université d'Istanbul et de l'hôpital Medipol Bahçelievler, en se concentrant sur les thymomes et autres tumeurs thoraciques malignes.

• Certifié par l'ESMO en oncologie médicale depuis 2022
• Rédiger des recherches sur les cancers thoraciques rares publiées dans des revues internationales
• Participer à 8 essais cliniques internationaux pour de nouveaux traitements contre le cancer
• Se spécialiser dans l'immunothérapie et les approches de thérapie ciblée

Le Dr Felix Dobritoiu utilise des techniques mini-invasives de pointe telles que la chirurgie robotique (da Vinci Xi) et la VATS uniportale pour le traitement du thymome à l'hôpital académique Ponderas.

• Spécialisé en chirurgie thoracique avec une expertise dans les résections médiastinales complexes
• Utiliser de petites incisions pour une récupération plus rapide et une douleur postopératoire réduite
• Réaliser des interventions sans drainage pleural postopératoire lorsque cela est possible
• Formé aux techniques avancées, y compris la procédure de Nuss

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.